190 related articles for article (PubMed ID: 20010526)
1. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation.
Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM
Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
3. Increased p53 immunoreactivity in proliferative inflammatory atrophy of prostate is related to focal acute inflammation.
Wang W; Bergh A; Damber JE
APMIS; 2009 Mar; 117(3):185-95. PubMed ID: 19245591
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis in prostate cancer: bax correlation with stage.
Amirghofran Z; Monabati A; Gholijani N
Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of cell proliferation, Bcl-2, p53, and caspase-3 expression on preneoplastic changes induced by cadmium and zinc chloride in the ventral rat prostate.
Arriazu R; Pozuelo JM; Henriques-Gil N; Perucho T; Martín R; Rodríguez R; Santamaría L
J Histochem Cytochem; 2006 Sep; 54(9):981-90. PubMed ID: 16585387
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
7. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
Bostwick DG; Qian J; Maihle NJ
Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
[TBL] [Abstract][Full Text] [Related]
8. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
9. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
[TBL] [Abstract][Full Text] [Related]
10. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
11. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate.
Wang W; Bergh A; Damber JE
Prostate; 2009 Sep; 69(13):1378-86. PubMed ID: 19507201
[TBL] [Abstract][Full Text] [Related]
12. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
13. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
[TBL] [Abstract][Full Text] [Related]
14. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions.
Dimitrakakis C; Kymionis G; Diakomanolis E; Papaspyrou I; Rodolakis A; Arzimanoglou I; Leandros E; Michalas S
Gynecol Oncol; 2000 Apr; 77(1):129-36. PubMed ID: 10739702
[TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
16. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
19. The utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and ductal adenocarcinoma.
Rioux-Leclercq N; Leray E; Patard JJ; Lobel B; Guillé F; Jouan F; Bellaud P; Epstein JI
Hum Pathol; 2005 May; 36(5):531-5. PubMed ID: 15948120
[TBL] [Abstract][Full Text] [Related]
20. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.
Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM
Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
